I think its base AUD 100-120 million now and double that on FDA ok on HDE for cholangio.
The value of the company on announcement of CE mark approval was higher than that 100 million. I agree, we have had no option but to burn cash waiting for Covid to pass, but it has passed and given the management team in place now (much better than on CE approval) we should be approaching that value again now.
The FDA approval won't be material in terms of revenue, but it will be in terms of clinician interest, research funding interest and attention from US investors.
Please look around at others for comparison. Remember they have an approved product that is selling in EU and AsiaP, with full funding for a reimbursement level clinical trial in Germany. That trial could also satisfy TGA, and could contribute to FDA NDA.
OSL Price at posting:
6.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)